# Cerebellopontine Angle Epidermoid Cyst With Malignant Transformation Into Squamous Cell Carcinoma: An Unusual Complication of a Benign Intracranial Tumor

**Authors:** Dianela Gasca Saldaña, Ytel Jazmin Garcilazo Reyes, José Omar Navarro, Daniel Magos Rodríguez, Luis Felipe Arias Ruiz, Maria Lizeth Perez Diaz, Erick Gomez-Apo, Raymundo Hernandez Montes de Oca, Guillermo Axayacalt Gutierrez-Aceves, Ildefonso R De La Peña, Andrés Vega-Rosas

PMC · DOI: 10.7759/cureus.86466 · 2025-06-20

## TL;DR

A rare case of a benign brain tumor turning into cancer is reported, showing how it was diagnosed and treated successfully.

## Contribution

This paper reports a rare case of epidermoid cyst transforming into squamous cell carcinoma and its treatment approach.

## Key findings

- Epidermoid cyst at cerebellopontine angle transformed into squamous cell carcinoma after 25 years.
- Treatment with radiotherapy, chemotherapy, and pembrolizumab showed clinical stability and good tolerance.

## Abstract

Epidermoid cysts (ECs) are typically located in the posterior cranial fossa, most commonly at the cerebellopontine angle (CPA). Although generally benign, the cyst’s epithelial lining can undergo malignant transformation into squamous cell carcinoma (SCC), a rare occurrence associated with poor prognosis. We present the case of a 55-year-old woman with a history of migraines who was incidentally diagnosed with a right CPA lesion consistent with an EC at the age of 30. Twenty-five years later, she developed progressive right-sided hearing loss, tinnitus, vertigo, headache, dysgeusia, and gait disturbances. Histopathological examination confirmed malignant transformation of the EC into SCC, supported by immunohistochemical markers including p63, p40, CK5/6, and D2-40. She was treated with fractionated stereotactic radiotherapy, carboplatin-paclitaxel chemotherapy, and the immune checkpoint inhibitor pembrolizumab, demonstrating good treatment tolerance and clinical stability.

## Linked entities

- **Proteins:** RPE65 (retinoid isomerohydrolase RPE65), IL9 (interleukin 9), ck56 (hypothetical protein), PDPN (podoplanin)
- **Chemicals:** carboplatin (PubChem CID 426756), paclitaxel (PubChem CID 36314)
- **Diseases:** hearing loss (MONDO:0005365), tinnitus (MONDO:0700322), squamous cell carcinoma (MONDO:0005096)

## Full-text entities

- **Genes:** TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}
- **Diseases:** EC (MESH:D005955), gait disturbances (MESH:D020233), CPA lesion (MESH:D009464), ECs (MESH:D004814), migraines (MESH:D008881), SCC (MESH:D002294), Intracranial Tumor (MESH:D009369), hearing loss (MESH:D034381), dysgeusia (MESH:D004408), tinnitus (MESH:D014012), vertigo (MESH:D014717), headache (MESH:D006261)
- **Chemicals:** pembrolizumab (MESH:C582435), paclitaxel (MESH:D017239), carboplatin (MESH:D016190)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12277640/full.md

---
Source: https://tomesphere.com/paper/PMC12277640